Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries

Authors

Avirup Guha, Case Western Reserve University
Prantesh Jain, Case Western Reserve University
Michael G Fradley, University of Pennsylvania
Daniel Lenihan, Washington University School of Medicine in St. Louis
Jahir M Gutierrez, Layer6 Inc.
Chhavi Jain, Cleveland Clinic
Marcos de Lima, Case Western Reserve University
Jill S Barnholtz-Sloan, Case Western Reserve University
Guilherme H Oliveira, University of South Florida
Afshin Dowlati, Case Western Reserve University
Sadeer Al-Kindi, Case Western Reserve University

Journal

Cancer Medicine

Publication Date

6-1-2021

Volume

10

Issue

12

First Page

3862

Last Page

3872

Document Type

Open Access Publication

DOI

10.1002/cam4.3938

Rights and Permissions

Guha, A., Jain, P., Fradley, M.G., Lenihan, D., Gutierrez, J.M., Jain, C., de Lima, M., Barnholtz-Sloan, J.S., Oliveira, G.H., Dowlati, A. and Al-Kindi, S. (2021), Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries. Cancer Med, 10: 3862-3872. https://doi.org/10.1002/cam4.3938 © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Recommended Citation

Guha, Avirup; Jain, Prantesh; Fradley, Michael G; Lenihan, Daniel; Gutierrez, Jahir M; Jain, Chhavi; de Lima, Marcos; Barnholtz-Sloan, Jill S; Oliveira, Guilherme H; Dowlati, Afshin; and Al-Kindi, Sadeer, "Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries." Cancer Medicine. 10, 12. 3862 - 3872. (2021).
https://digitalcommons.wustl.edu/open_access_pubs/10740